Katz Barrett
Known title: Chief Medical OfficerCIK: 0001841628
Associated companies
Transaction History
| VRDN | ▲ Buy | Option Exercise | 24,853 | $572K | 1/17/2023 | View on chart |
| VRDN | ▼ Sell | Open Market | 24,853 | $925K | 1/17/2023 | View on chart |
| VRDN | ▲ Buy | Option Exercise | 4,147 | $96K | 1/13/2023 | View on chart |
| VRDN | ▼ Sell | Open Market | 4,147 | $153K | 1/13/2023 | View on chart |
| VRDN | ▼ Sell | Open Market | 47,377 | $1.7M | 1/10/2023 | View on chart |
| VRDN | ▲ Buy | Option Exercise | 47,377 | $1.1M | 1/10/2023 | View on chart |
| VRDN | ▲ Buy | Option Exercise | 12,623 | $291K | 1/9/2023 | View on chart |
| VRDN | ▼ Sell | Open Market | 12,623 | $417K | 1/9/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Roche wins FDA approval for home thyroid eye disease therapy
Roche received FDA approval for the first at-home treatment for thyroid eye disease, a development relevant to Viridian Therapeutics as it operates in the same therapeutic space. While Viridian's stock is currently trading near its 52-week low, analysts maintain an average price target significantly higher than the current market price. The news highlights competitive dynamics in the thyroid eye disease market that investors may be monitoring.
Roche wins FDA approval for home thyroid eye disease therapy. Roche received FDA approval for the first at-home treatment for thyroid eye disease, a development relevant to Viridian Therapeutics as it operates in the same therapeutic space. While Viridian's stock is currently trading near its 52-week low, analysts maintain an average price target significantly higher than the current market price. The news highlights competitive dynamics in the thyroid eye disease market that investors may be monitoring.